Background & Purpose

The purpose of this study is to evaluate the benefit of Exenatide-ER for maintaining diabetic cats in remission (in an insulin-independent state).

Participation Requirements

**Inclusion Criteria:**
- Cats that are in good body condition (i.e., not underweight) and diagnosed as diabetic with a recent onset of remission according to the following criteria:
  - Previous diagnosis of diabetes mellitus based on clinical signs and a high serum fructosamine
  - Treated with insulin for at least 2 weeks
  - Has not required insulin treatment for 4 to 12 weeks
  - Has no current evidence of diabetes relapse
  - Routinely fed a diabetic diet

**Exclusion Criteria:**
- Cats -
  - Recently given (within the last 2 months) oral hypoglycemic agents
  - With significant concurrent disease and/or overt evidence of peripheral neuropathy, acromegaly and/or untreated hyperthyroidism.
- Cats will not be excluded if they have controlled hyperthyroidism or are receiving methimazole and/or ACE-inhibitors.

Procedures

- Blood tests (complete blood count, biochemistry panel, serum fructosamine concentrations T4, fPLI and IGF-1) and urinalysis to determine eligibility
- If determined to be eligible and you decide to participate, your cat will be randomly placed into one of the two treatment group: Exenatide-ER (Bydureon®) or placebo, and receive the first injection.
- At each monthly recheck (starting 27-32 days after initial injection), a blood sample will be drawn to measure blood glucose levels and if needed, serum fructosamine.

Owner Responsibilities

- Bringing your cat in to be rechecked once a month until your cat is no longer in remission for up to 24 months

Benefits

- The study will pay for one third of the cost of the first office visit as well the full cost of screening tests (including urinalysis and blood tests – CBC, Chem, T4, fPLI and IGF-1) – as well as all drug expenses and all follow-up visits.
- The study will give you a $35 gift card (for a maximum total of $805) after every recheck exam.
- Participation in this trial may help to increase duration of remission, increase numbers and improved function of cells that secrete insulin in the pancreas, and help with weight loss (if your cat is over weight).